325 related articles for article (PubMed ID: 35956886)
21. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
22. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
23. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
[TBL] [Abstract][Full Text] [Related]
24. Fibroelastic pseudotumor elastofibroma dorsi detected by
Oporto M; Cepa F; Orta N; Rubí S; Navalón H; Peña C
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):46-49. PubMed ID: 28522155
[TBL] [Abstract][Full Text] [Related]
25. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
26. Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals.
Lauri C; Di Traglia S; Galli F; Pizzichini P; Signore A
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):105-15. PubMed ID: 25737424
[TBL] [Abstract][Full Text] [Related]
27. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
28. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer.
Fu H; Fu J; Huang J; Pang Y; Chen H
Clin Nucl Med; 2021 Nov; 46(11):940-942. PubMed ID: 34034326
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
[TBL] [Abstract][Full Text] [Related]
32.
Wu D; Ylli D; Heimlich SL; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2019 Nov; 29(11):1523-1535. PubMed ID: 31452449
[No Abstract] [Full Text] [Related]
33. Utility of non-contrast Dual Energy Computed Tomography in diagnosis of differentiated thyroid cancer - two case study.
Durma AD; Saracyn M; Zegadło A; Kamiński G
Cancer Imaging; 2023 Apr; 23(1):39. PubMed ID: 37072868
[TBL] [Abstract][Full Text] [Related]
34. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
36. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
37. PET/CT imaging of thyroid cancer.
Mosci C; Iagaru A
Clin Nucl Med; 2011 Dec; 36(12):e180-5. PubMed ID: 22064103
[TBL] [Abstract][Full Text] [Related]
38. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
39. Advanced imaging and theranostics in thyroid cancer.
Roseland ME; Dewaraja YK; Wong KK
Curr Opin Endocrinol Diabetes Obes; 2022 Oct; 29(5):456-465. PubMed ID: 36068937
[TBL] [Abstract][Full Text] [Related]
40. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Stahl A; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1():S48-56. PubMed ID: 21484380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
